Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
about
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
description
clinical trial
@en
name
Phase II Study for Combination ...... tatic Adrenocortical Carcinoma
@en
type
label
Phase II Study for Combination ...... tatic Adrenocortical Carcinoma
@en
prefLabel
Phase II Study for Combination ...... tatic Adrenocortical Carcinoma
@en
P1476
Phase II Study for Combination ...... tatic Adrenocortical Carcinoma
@en
P3098
NCT04318730
P4844
P580
2020-04-01T00:00:00Z
P582
2023-04-01T00:00:00Z